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The malfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl channel is associated with a wide spectrum of
disease. In the search for modulators of CFTR, pharmaceutical agents have been identified that (i) act indirectly by regulating the protein kinases
and phosphatases, which control CFTR, and (ii) interact directly with CFTR. Some agents modulate CFTR by altering the function of the
nucleotide-binding domains (NBDs) that control channel gating, whereas others inhibit CFTR by preventing Cl flow through the channel pore.
Knowledge of CFTR modulators might lead to new understanding of the CFTR Cl channel, its physiological role and malfunction in disease.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR; Chloride ion channel; CFTR opener; CFTR blocker; Cystic fibrosis; Drug therapy1. Introduction
The cystic fibrosis transmembrane conductance regulator
(CFTR; [1]) is an ATP-binding cassette (ABC) transporter
that forms a Cl channel with complex regulation (for a
review, see Refs. [2,3]). CFTR is predominantly located in
the apical membrane of epithelia where it regulates trans-
epithelial fluid and electrolyte transport [4]. A wide spec-
trum of disease is associated with the malfunction of CFTR
(known as ‘CFTR-opathies’) including cystic fibrosis (CF),
male infertility disorders, secretory diarrhoea and polycystic
kidney disease [4]. This suggests that pharmacological
agents, which modulate CFTR Cl currents, might be used
to treat disease. These agents might also serve as valuable
probes to identify CFTR and investigate its structure and
function. In the search for modulators of CFTR, several
pharmacological strategies to manipulate CFTR Cl cur-1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.030
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centration; i, single-channel current amplitude; IBMX, 3-isobutyl-1-
methylxanthine; MPB, benzo[c]quinolizinium; MSD, membrane-spanning
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domain.
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E-mail address: D.N.Sheppard@bristol.ac.uk (D.N. Sheppard).rents have been identified [5,6]. These studies also demon-
strate that CFTR has a distinct pharmacological profile.
CFTR Cl channels are enhanced by flavonoids (e.g.,
genistein), substituted benzimidazolones (e.g., NS004) and
xanthines (e.g., 3-isobutyl-1-methylxanthine, IBMX; see
Tables 1 and 2 of Ref. [7]). In contrast, CFTR Cl currents
are inhibited by sulphonylureas (e.g., glibenclamide), ary-
laminobenzoates [e.g., 5-nitro-2-(3-phenylpropylamino)-
benzoic acid, NPPB] and the thiazolidinone CFTRinh-172
(see Tables 3–5 of Ref. [7]). Importantly, disulphonic
stilbenes (e.g., 4,4V-diisothiocyanatostilbene-2,2V-disul-
phonic acid, DIDS; [8]) and calixarenes (e.g., calix[4]arene;
[9]) are without effect when added to the extracellular side
of the membrane. The failure of extracellular disulphonic
stilbenes and calixarenes to inhibit the CFTR Cl channel
distinguishes CFTR from other epithelial Cl channels that
are blocked by these agents [5].
Protocol D.10.2. of the European Working Group on
CFTR Expression [7] lists many agents that modulate the
CFTR Cl channel while protocol D.10.1. [10] discusses
experiments to elucidate the mechanism of action of these
agents. Here we provide an overview of these protocols.2. Openers of the CFTR Cl channel
CFTR is controlled by the phosphorylation (P) of the
regulatory domain (R) and the interaction of nucleosideed by Elsevier B.V. All rights reserved.
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[2,3]). Some agents that potentiate CFTR Cl currents act
indirectly by regulating the activity of the protein kinases
and phosphatases that control tightly the phosphorylation
status of CFTR (see Table 1 of Ref. [7]). There are data
suggesting that agents, which increase intracellular cAMP
levels, might augment CFTR Cl currents [7]. However,
most agents inhibit the protein phosphatases that dephos-
phorylate CFTR [7]. In the presence of ATP, but in the
absence of protein kinase A (PKA), these agents augment
CFTR Cl currents.
Other drugs potentiate CFTR Cl currents by interacting
directly with CFTR to alter channel gating (see Table 2 of
Ref. [7]). Based on their effects on channel gating, many
CFTR openers interact with the NBDs to enhance CFTR
Cl currents [7]. However, some agents interact with the R
domain, and for others, their binding site(s) have yet to be
identified [7].3. Inhibitors of the CFTR Cl channel
A variety of agents with diverse chemical structures
inhibit the CFTR Cl channel [5,6]. In general, these agents
have several characteristics in common: they are anions,
most are lipophilic and many are large in size.
Two mechanisms of inhibition of the CFTR Cl channel
are distinguished: open-channel and allosteric block. Open-
channel blockers inhibit CFTR by binding within the CFTR
pore and preventing Cl flow by occluding the permeation
pathway (Fig. 1; see Table 3 of Ref. [7]). As a result, in the
presence of these agents, channel openings are interrupted
by drug-induced blocking events (see Fig. 1 of Ref. [11]). InFig. 1. Large anions inhibit CFTR by an open-channel block mechanism. This si
CFTR Cl channel. Schematic single-channel traces are shown below the models:
intracellular end of the channel pore and preventing Cl permeation. For discussion
binding sites formed by sequences from both NBD1 and NBD2.contrast, allosteric blockers inhibit CFTR by greatly slowing
the rate of channel opening (Fig. 2; see Table 4 of Ref. [7]).
As a result, in the presence of these agents, the duration of
closed periods separating channel openings is prolonged
greatly (see Fig. 7 of Ref. [12]).4. Distinguishing CFTR openers and blockers
To identify CFTR modulators and investigate their
mechanism of action, we use the patch-clamp technique to
study CFTR Cl currents in excised inside-out membrane
patches from mammalian cells expressing recombinant
wild-type (wt) human CFTR [13]. Following the activation
of CFTR Cl currents by cAMP-dependent phosphoryla-
tion, we add drugs to the solution bathing the intracellular
side of the membrane. To compensate for any channel
rundown during prolonged recordings and test for revers-
ibility, we compare specific interventions with the average
of pre- and postintervention control periods.
If increasing concentrations of a drug cause a concentra-
tion-dependent increase in CFTR Cl current, we conclude
that the drug potentiates CFTR Cl current (e.g., NS004;
[14]). However, if increasing concentrations of a drug cause
a concentration-dependent decrease in CFTR Cl current,
we conclude that the drug inhibits CFTR (e.g., glibencla-
mide; [15]). Because some CFTR openers inhibit channel
activity at elevated concentrations, we test a wide range of
drug concentrations to ascertain whether a drug has dual
effects on CFTR (e.g., genistein; [12]).
To determine whether cAMP-dependent phosphorylation
is a prerequisite for the interaction of drugs with CFTR, we
examine the effect of drugs on CFTR Cl currents in themplified model shows the effect of large anions (A) on the activity of the
C, closed state; O, open state. Large anions inhibit CFTR by occluding the
, see Ref. [6]. The black hexagons represent ATP molecules interacting with
Fig. 2. Genistein blocks CFTR by an allosteric mechanism. This simplified model shows the effect of elevated genistein (G) concentrations on the activity of
the CFTR Cl channel. Elevated genistein concentrations inhibit CFTR principally by slowing greatly the rate of channel opening. Because elevated
concentrations of ATP relieve genistein inhibition of CFTR, we propose that genistein and ATP compete for a common binding site. For discussion, see Ref.
[32]. Other details as in Fig. 1.
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for a drug to increase channel activity, we conclude that the
drug likely interacts directly with CFTR (e.g., genistein;
[6]). To demonstrate that a drug stimulates CFTR by
inhibiting protein phosphatases, studies using both electro-
physiology and protein biochemistry are required (for fur-
ther information, see Refs. [16,17]).
To learn how the drug reaches its binding site, we
compare the efficacy of the drug from the extra- and
intracellular sides of the membrane. If the effects of a drug
are slow in onset and difficult to reverse when added to the
extracellular side of the membrane but rapid in onset and
easily reversible when added to the intracellular side of the
membrane, we would make two conclusions. First, that the
drug-binding site is located on the intracellular side of the
membrane. Second, that the drug is too large to pass through
this channel to reach its binding site when present in the
extracellular solution. Instead, the drug must cross the cell
membrane to reach its binding site. An example of a CFTR
blocker exhibiting these characteristics is glibenclamide
[15,18,19].
By investigating the effects of drugs on the single-
channel activity of CFTR, we obtain a molecular explana-
tion for the quantitative changes in CFTR Cl current
caused by different drugs. Macroscopic and single-channel
activities are related by the equation:
I ¼ N  i Po; ð1Þ
where I is the macroscopic current, N is the number of active
channels, i is the amount of current flowing through a single
channel and Po is the open probability of a single channel.
To identify the mechanism of action of CFTR modulators,we investigate the effects of drugs on i and Po using
membrane patches that contain only a few active channels.5. Mechanism of drug potentiation of CFTR
In principal, a drug might potentiate CFTR Cl currents
in one of three ways: (i) by increasing the number of active
channels, (ii) by enhancing current flow through open
channels and (iii) by altering channel gating. For these
studies, we generally choose a drug concentration twofold
higher than that causing half-maximal stimulation of CFTR.
By visual inspection of single-channel records, we deter-
mine whether a drug enhances the number of active chan-
nels in a membrane patch. By measuring i and Po, we
determine whether a drug augments CFTR Cl current by
increasing current flowing through open channels or altering
channel gating, respectively. If a drug is without effect on N
and i but increases Po, we conclude that the drug potentiates
CFTR by altering channel gating (e.g., phloxine B; [20]).
To determine how a drug potentiates CFTR by altering
channel gating, we investigate the kinetics of channel gating
using membrane patches that contain only a single active
channel. We analyse the duration of bursts of channel
openings following the protocol of Carson et al. [21] using
a tc (the time that separates interburst closures from intra-
burst closures) determined by analyses of closed-time histo-
grams. Closures longer than tc are considered to define
interburst closures, whereas closures shorter than this time
are considered gaps within bursts. If a drug is without effect
on mean burst duration but decreases significantly the
interburst interval, we conclude that the drug potentiates
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opening (e.g., bromotetramisole; [22]). In contrast, if a drug
is without effect on the interburst interval but dramatically
increases mean burst duration, we conclude that the drug
enhances CFTR Cl current by slowing the rate of channel
closure (e.g., phloxine B; [20]).
To learn whether a drug augments CFTR Cl current by
competing with ATP for a common binding site, we
examine the effect of ATP concentration on the drug
potentiation of CFTR Cl currents. If a drug decreases the
ATP concentration required for half-maximal stimulation of
CFTR (Km) without altering the maximum Po (Pomax), these
data would suggest that the drug increases the affinity of
ATP for CFTR. They would also suggest that the drug and
ATP might interact with a common binding site on CFTR.
However, if the drug decreases Km but increases Pomax, we
would interpret this result to suggest that the drug might
interact with a site distinct from the ATP binding site to
increase the affinity of ATP for CFTR (e.g., phloxine B;
[20]). Finally, to identify the amino acid residues that
contribute to drug-binding sites, studies using CFTR var-
iants containing site-directed mutations are required [23].6. Mechanism of drug inhibition of CFTR
To investigate how drugs block the CFTR Cl channel,
we generally test the effect on the single-channel activity of
CFTR of a drug concentration twofold higher than that
causing half-maximal inhibition of CFTR. We inspect
visually the drug’s effects on the channel and measure i
and Po. If channel block is characterised by numerous drug-
induced closures interrupting channel openings and the drug
dramatically decreases Po, but is without effect on i, we
conclude that the drug blocks CFTR with ‘‘intermediate’’
speed [24] (e.g., glibenclamide; Fig. 3 and [15]). In contrast,
if channel block is characterised by a decrease in current
amplitude, increased open-channel noise, but normal chan-
nel gating, and the drug dramatically decreases i, but is
without effect on Po, we conclude that the drug blocks
CFTR with ‘‘very fast speed’’ [24] (e.g., tolbutamide; [25]
and niflumic acid (NFA); Fig. 3 and [26]).
Noise analysis is required to quantify CFTR inhibition by
drugs that block with ‘‘very fast speed’’ [25–27], whereas
single-channel studies may be employed to quantify CFTR
inhibition by drugs that block with ‘‘intermediate speed’’
[11,13,15]. For the latter studies, we generate events lists,
create open- and closed-time histograms and fit histograms
with one or more component exponential functions using
the maximum likelihood method. In the absence of drugs,
open- and closed-time histograms of CFTR are best fit with
one- (sO) and two-component functions (sC1 and sC3),
respectively [28]. If in the presence of a drug, open- and
closed-time histograms are best fitted by one- (sO) and
three-component functions (sC1, sC2 and sC3), we would
interpret this result to suggest that the drug inhibits CFTRby generating a new population of channel closures de-
scribed by an intermediate closed-time constant (sC2) (e.g.,
glibenclamide; [15]). This new population of channel clo-
sures represents channel-blocking events.
To investigate further the kinetics of channel block, we
examine the effects of different concentrations of the drug
on open- and closed-time constants. If closed-time constants
do not change significantly with drug concentration, but
increasing concentrations of the drug lead to a dramatic
decrease in channel open-time, we would conclude that the
drug is an open-channel blocker of CFTR (e.g., glibencla-
mide; [15]). The effects of an open-channel blocker on
CFTR may be described by the simple kinetic model:
CX
b
a
O X
kon½Drug
koff
B; ð2Þ
where C, O and B represent the closed, open and blocked
states of the channel, respectively; b and a are the transition
rates for channel opening and closing; kon is the second-
order binding constant for drug binding to CFTR; and
koff is the first-order rate constant for drug dissociation
from CFTR. The equilibrium dissociation constant for
drug binding to CFTR, Kd = koff/kon; koff = 1/sC2; and
kon=(1/sO) [Drug] 1. A plot of drug concentration versus
the reciprocal of the drug-induced closed-time constant is a
flat line. In contrast, a plot of drug concentration versus the
reciprocal of the open-time constant increases steeply as the
concentration of drug rises (see Fig. 5 of Ref. [10]).
For the ‘‘intermediate speed’’ blocker glibenclamide,
kon = 3.5 106 M 1 s 1, koff = 92 s 1 and Kd = 26 AM at
 50 mV [15]. For the ‘‘very fast speed’’ blocker tolbuta-
mide, kon = 2.8 106 M 1 s 1, koff = 1210 s 1 and Kd =
430 AM [25]. These data provide an explanation for why
glibenclamide is a more potent inhibitor of CFTR than
tolbutamide. Although both drugs bind rapidly to CFTR,
glibenclamide remains bound to CFTR more than 10-fold
longer than tolbutamide.
A defining characteristic of the closed X open X blocked
kinetic scheme (Eq. (2)) is that in the presence of the
blocker, the mean open time per burst is unaltered; the burst
is simply prolonged by numerous intervening visits to the
blocked state [29]. To test whether the closed X open X
blocked scheme well describes the drug block of CFTR, we
examine the effect of drug concentration on mean burst
length. Mean burst length can be calculated using the
relationship [29]:
Mean burst length ¼ a1ð1þ ½Drug=KdÞ; ð3Þ
In the absence of drug, a = 1/sO and Kd = koff/kon, with kon
and koff calculated as described above. If a drug is an open-
channel blocker of CFTR, then Eq. (3) predicts that the
mean burst length increases linearly with the concentration
of the drug [29]. Thus, using these strategies, we determine
whether the inhibition of the CFTR Cl channel by a drug is
Fig. 3. Intermediate speed and very fast block of the CFTR Cl channel. The traces show the effects of glibenclamide (glib; 25 AM) and niflumic acid (NFA;
200 AM) on the single-channel activity of CFTR. ATP (0.3 mM) and PKA (75 nM) were continuously present in the intracellular solution. Voltage was  50
mV, and there was a large Cl concentration gradient across the membrane patch ([Cl]I, 147 mM; [Cl
]E, 10 mM). Expanded 1-s recordings are shown below
the prolonged traces. Dashed lines indicate where channels are closed and downward deflections correspond to channel openings. Glibenclamide (25 AM) and
niflumic acid (200 AM) were tested on two different single-channel patches. Other details as in Ref. [15]. Modified, with permission, from Ref. [15].
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scheme and quantify the interaction between CFTR and the
drug.7. Distinguishing open-channel and allosteric blockers of
the CFTR Cl channel
In principal, a drug might inhibit CFTR by one of two
mechanisms: open-channel or allosteric block (Figs. 1 and
2; [7]). Because the characteristics of open-channel and
allosteric block differ strikingly, agents that act by these
different mechanisms can be discriminated using three series
of experiments as follows:
Voltage dependence: Inhibition of CFTR by open-chan-
nel blockers is voltage-dependent: negative voltages drive
open-channel blockers (large anions) into the CFTR pore
where they occlude the channel preventing Cl permeation
[15,30,31]. In contrast, positive voltages repel open-channel
blockers from their binding site relieving inhibition
[15,30,31]. Inhibition by allosteric blockers is voltage-inde-
pendent because the NBDs and R domain that control
channel gating are located outside the transmembrane elec-
tric field [2,3].
To investigate the voltage dependence of channel block,
we bathe membrane patches in symmetrical Cl-rich sol-
utions and record CFTR Cl currents in the absence and
presence of the drug over the voltage range F 100 mV
using a voltage ramp protocol. If a drug dramatically
decreases CFTR Cl current at negative voltages, but atpositive voltages is without effect, we conclude that drug
inhibition is voltage-dependent (e.g., glibenclamide; [15]).
In contrast, if a drug decreases CFTR Cl current by similar
amounts at all voltages, we conclude that drug inhibition is
voltage-independent (e.g., genistein; [32]).
Effect of the external Cl  concentration: Inhibition of
CFTR by open-channel blockers is sensitive to the external
Cl concentration ([Cl]E) because open-channel blockers
might compete with Cl ions for a common binding site
within the CFTR pore [15,33,34]. When [Cl]E is reduced,
open-channel blockers bind more avidly within the CFTR
pore. However, when [Cl]E is increased, Cl
 ions entering
the pore from the opposite end to that of the open-channel
blocker repel the open-channel blocker from its binding site.
Channel block by allosteric blockers is unaffected by
altering [Cl]E because the NBDs and R domain do not
contribute to the CFTR pore [2,3].
To investigate the effect of [Cl]E on channel block, we
compare the voltage dependence of channel block when
[Cl]E is 10 and 147 mM. If a drug blocks CFTR more
avidly when [Cl]E is 10 mM compared with when [Cl
]E
is 147 mM, we conclude that reducing [Cl]E enhances the
potency of drug inhibition of CFTR (e.g., glibenclamide;
[15]). In contrast, if channel block in the presence of 10 and
147 mM [Cl]E are equivalent, we conclude that reducing
[Cl]E is without effect on the potency of drug inhibition of
CFTR (e.g., genistein; [32]).
Effect of pyrophosphate: Inhibition of CFTR by allosteric
blockers is relieved by the inorganic phosphate analogue
pyrophosphate (PPi; [35]) because CFTR inhibition by
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and hydrolysis that controls channel gating [2,3]. In the
absence of PPi, the gating cycle is short and CFTR makes
frequent transitions to the closed state where it is inhibited
by allosteric blockers. In contrast, in the presence of PPi, the
gating cycle is prolonged and CFTR makes infrequent
transitions to the closed state.
To investigate the effects of PPi on channel block, we
compare the magnitude of drug inhibition before and after
CFTR potentiation by PPi (5 mM). If PPi relieves channel
block, we conclude that the drug might inhibit CFTR by an
allosteric mechanism (e.g., genistein; [32]). In contrast, if
PPi is without effect on channel block, we conclude that the
drug likely inhibits CFTR by an open-channel block mech-
anism (e.g., glibenclamide; [15]).
To summarise, inhibition of CFTR by open-channel
blockers is voltage-dependent and enhanced when [Cl]E
is reduced but unaffected by PPi. In contrast, inhibition of
CFTR by allosteric blockers is voltage-independent and
unaffected by reducing [Cl]E but relieved by PPi and
elevated concentrations of ATP. In closing this section, a
note of caution is warranted. Some drugs might exhibit
some, but not all, the characteristics of open-channel or
allosteric block (e.g., NFA; [26]), whereas other drugs might
inhibit CFTR by both mechanisms (e.g., genistein; [32]).8. Location of drug-binding sites
Information about the location of drug-binding sites
within the transmembrane electric field can be obtained by
analysis of the voltage dependence of block using the
Woodhull relationship (for discussion, see Ref. [10]). These
analyses demonstrate that open-channel blockers may tra-
verse about half the membrane electric field from the
intracellular side to reach their binding sites (e.g., gliben-
clamide; [11,15]). Because open-channel blockers are often
large anions, this result suggests that the CFTR pore has a
wide deep intracellular vestibule where large anions bind to
inhibit Cl permeation (Fig. 1). In contrast, for CFTR
blockers that act by an allosteric mechanism, the fraction
of the membrane electric field that the blocker traverses to
reach its binding site is close to 0 (e.g., genistein; [32]). This
suggests that allosteric blockers inhibit CFTR by interacting
with sites located on the intracellular side of the membrane
outside the electric field of the membrane (Fig. 2). Finally,
with information derived from analyses of channel block
using the Woodhull relationship, studies of CFTR variants
containing site-directed mutations may identify amino acid
residues that contribute to drug-binding sites [23,30,33].9. Conclusion
In recent years, there has been a surge in the number of
CFTR modulators identified. However, the lack of potencyand especially specificity hinders the use of virtually all
currently available CFTR modulators.
In the case of CFTR activators, bromotetramisole is a
valuable tool to inhibit the protein phosphatases that de-
phosphorylate CFTR and deactivate the channel [17]. Gen-
istein is the CFTR opener of choice. It enhances CFTR Cl
currents in both cells expressing recombinant CFTR [12]
and epithelia expressing native CFTR [36]. The substituted
benzo[c]quinolizinium (MPB) compounds appear to hold
great promise as CFTR openers. While their potency at
present is suboptimal, MPB compounds (i) correct defects in
the biosynthesis of CFTR, (ii) augment CFTR Cl currents
and (iii) are without effect on other types of Cl channels
[37,38]. These data suggest that MPB compounds are
valuable lead compounds for the development of therapeu-
tically active CFTR openers.
In the case of CFTR inhibitors, glibenclamide has proved
to be a popular tool to inhibit the CFTR Cl channel.
However, the effects of voltage and [Cl]E on channel
block by glibenclamide necessitate that experimental con-
ditions are carefully controlled to maximise CFTR inhibi-
tion by the drug [11,15]. The failure of suramin to block
CFTR when added to the extracellular side of the membrane
[39] highlights the importance of testing the effects of novel
CFTR modulators from both sides of the membrane. CFTR
blockers that warrant further investigation include oestro-
gens, fatty acids and fluorescein derivatives [20,40,41].
Finally, the successful identification of novel CFTR
modulators by high-throughput screening of libraries of
chemicals (e.g., CFTRinh-172; [42]), suggests that we
should be optimistic about the prospects for the develop-
ment of potent, specific CFTR modulators.Acknowledgements
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